Your browser is no longer supported. Please, upgrade your browser.
Settings
ATNM Actinium Pharmaceuticals, Inc. daily Stock Chart
ATNM [AMEX]
Actinium Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.13 Insider Own0.90% Shs Outstand395.16M Perf Week-35.02%
Market Cap155.13M Forward P/E- EPS next Y-0.05 Insider Trans0.00% Shs Float369.62M Perf Month5.66%
Income-21.90M PEG- EPS next Q-0.01 Inst Own13.30% Short Float1.17% Perf Quarter106.30%
Sales- P/S- EPS this Y34.20% Inst Trans118.21% Short Ratio0.20 Perf Half Y63.69%
Book/sh0.02 P/B19.49 EPS next Y28.60% ROA-150.60% Target Price- Perf Year71.01%
Cash/sh0.01 P/C26.29 EPS next 5Y- ROE-255.40% 52W Range0.16 - 0.65 Perf YTD79.10%
Dividend- P/FCF- EPS past 5Y30.50% ROI- 52W High-39.92% Beta1.80
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin- 52W Low148.34% ATR0.06
Employees25 Current Ratio1.40 Sales Q/Q- Oper. Margin- RSI (14)38.33 Volatility13.07% 13.25%
OptionableYes Debt/Eq0.13 EPS Q/Q32.30% Profit Margin- Rel Volume1.10 Prev Close0.43
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume21.71M Price0.39
Recom1.70 SMA20-20.53% SMA50-5.02% SMA20043.72% Volume23,922,550 Change-8.28%
Dec-06-17Initiated B. Riley FBR, Inc. Buy $2.75
Oct-23-17Resumed ROTH Capital Buy $6
Sep-14-17Initiated Maxim Group Buy $3
Aug-25-16Initiated ROTH Capital Buy $5
Feb-29-16Initiated H.C. Wainwright Buy $8
Oct-15-15Initiated FBR Capital Outperform $12
Oct-01-14Initiated MLV & Co Buy $16
Jul-22-14Initiated Canaccord Genuity Buy $16
Aug-10-20 02:30PM  
12:00PM  
Aug-04-20 05:45PM  
Aug-03-20 11:54AM  
Jul-28-20 05:50PM  
Jul-27-20 11:30AM  
Jul-23-20 12:00PM  
Jul-21-20 08:57AM  
Jul-20-20 10:32AM  
Jul-15-20 07:03AM  
Jul-09-20 11:30AM  
Jul-08-20 09:05AM  
Jun-19-20 05:15PM  
Jun-17-20 11:30AM  
Jun-16-20 11:30PM  
04:01PM  
Jun-15-20 11:29PM  
Jun-12-20 08:43AM  
Jun-09-20 08:47AM  
Jun-04-20 09:45PM  
09:42AM  
Jun-03-20 09:53AM  
Apr-24-20 05:15PM  
Apr-21-20 11:35PM  
04:01PM  
Apr-16-20 07:00AM  
Apr-12-20 09:02AM  
Mar-06-20 10:56AM  
Mar-05-20 07:30AM  
Feb-26-20 07:33AM  
Feb-25-20 09:33AM  
Feb-21-20 07:30AM  
Feb-13-20 08:03AM  
Feb-05-20 05:50PM  
08:03AM  
Jan-30-20 05:45PM  
Jan-13-20 12:00PM  
07:15AM  
07:03AM  
Jan-07-20 07:03AM  
Jan-03-20 11:30AM  
Jan-02-20 09:29AM  
Dec-22-19 05:08PM  
Dec-09-19 06:10AM  
06:00AM  
Dec-07-19 08:35AM  
Dec-01-19 09:30AM  
Nov-20-19 09:00AM  
Nov-07-19 04:05PM  
Nov-06-19 09:15AM  
09:00AM  
Oct-28-19 08:20AM  
Oct-15-19 10:48AM  
Sep-30-19 08:00AM  
Sep-23-19 08:00AM  
Sep-16-19 08:00AM  
Jul-23-19 08:00AM  
Jul-17-19 12:56PM  
Jul-11-19 08:00AM  
Jun-26-19 08:00AM  
Jun-25-19 08:00AM  
Jun-20-19 08:00AM  
Jun-04-19 08:00AM  
May-24-19 01:40PM  
May-16-19 08:00AM  
May-07-19 08:00AM  
Apr-18-19 09:00AM  
Apr-17-19 04:01PM  
Apr-08-19 08:00AM  
Apr-04-19 09:57AM  
Apr-03-19 09:16AM  
08:00AM  
Apr-01-19 09:00AM  
Mar-29-19 08:00AM  
Mar-26-19 08:00AM  
Mar-20-19 08:00AM  
Mar-19-19 05:05PM  
05:00PM  
Mar-15-19 05:05PM  
08:00AM  
Mar-07-19 12:15PM  
Feb-25-19 02:20PM  
08:00AM  
Feb-21-19 08:00AM  
Feb-15-19 07:40AM  
Feb-12-19 08:00AM  
Feb-06-19 08:00AM  
Feb-05-19 08:00AM  
Feb-04-19 08:00AM  
Jan-29-19 08:00AM  
Jan-25-19 08:00AM  
Jan-23-19 08:00AM  
Jan-17-19 08:00AM  
Jan-16-19 08:00AM  
Jan-03-19 08:00AM  
Dec-21-18 02:08PM  
Dec-04-18 08:00AM  
Dec-03-18 08:00AM  
Nov-19-18 08:00AM  
Nov-05-18 08:00AM  
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.